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Table S1. Summary of docking run is provided including, Docking score, number of poses obtained, pose rank number, orientation of ligand in the binding pocket, and various energy terms are summarized. Ligand-binding poses those highlighted in green are used for MD simulations. 
band, blue lines; 95% prediction band, red lines). The fitting parameters were for the open form: A 1 = 0.79 Å, τ 1 = 3.76 ps and A 2 = 1.95 Å, τ 1 = 2.948 ns, and for the closed form: A 1 = 1.74 Å, τ 1 = 94.93 ps and A 2 = 9.03 Å, τ 1 = 213.675 ns. Using these values, an average time for stabilization of RMSD fluctuations can be derived according to , giving τ av = 2.1 ns and τ av = 179.0 ns for the open and
closed form of NPC1L1-NTD, respectively. Figure S10. Contribution of residues being mutated in low cholesterol absorbers to the binding free energy in NPC1L1-NTD. Decomposed change in Gibbs free energy upon binding to cholesterol for residues studied in a computational mutation analysis in Fig. 5 , main text. Results are shown as mean ± standard error from 2000 snapshots generated every 20 psec from a total trajectory length of 20 nsec.
Figure S11. Position of representative residues whose mutation leads to impaired binding of cholesterol. Shown is the binding pose with cholesterol in green and relevant residues, Ile106, Thr128 and Thr61, shown in van der Waals representation for the wild-type NPC1L1-NTD (most left panel). Mutant NPC1L1-NTDs are shown with Met61 instead of Thr61 (second left panel), Ala106 instead of Ile106 (second right panel) and Ala128 instead of Thr128 (most right panel). Mutated residues and sterol ligands are shown as van der Waals spheres in coloring based on elements (residues) or as green steroid backbone with red 3'-hydroxy group (sterol ligands), respectively.
Figure S12. Location of Ala108 in NPC1L1-NTD and Q92 in NPC1-NTD relative to the binding pocket. A108 in NPC1L1-NTD corresponds to Q92 in NPC1-NTD, and both residues are located distal to the mouth of the binding pocket. Overlay of the secondary structure of NPC1-NTD (green) and NPC1L1-NTD (beige) with cholesterol in the binding pose. Left panel, overview; right panel zoom of entangled region.
